News
Warsaw-based machine learning company selected for EU’s Global Gateway business advisory group
The Global Gateway initiative aims to narrow the global investment gap and mobilise up to €300bn in investments
The Warsaw-based machine learning company MIM Solutions will represent Poland in EU’s Global Gateway business advisory group.
Global Gateway is a strategy, launched by the European Commission and the EU High Representative, with the aim of boosting smart and secure links in digital, energy and transport sectors and strengthening health, education and research systems.
The mission of the programme is to narrow the global investment gap worldwide, in the light of the recent Covid-19 pandemic and the Russian invasion of Ukraine.
The initiative aims to mobilise up to €300bn in investments through a Team Europe approach, bringing together the EU, its member states and their financial and development institutions.
MIM Solutions, a spin-off of the Faculty of Mathematics, Informatics and Mechanics at the University of Warsaw, uses AI and machine learning to advance outcomes in medicine and reproductive health.
The company has joined the group of advisors to the European Commission alongside giants such as Siemens, Orange, Nokia, and Veolia.
The list of new members of the advisory group was announced on September 18 during the Sustainable Development Goals (SDG) Summit in New York by the EU Commissioner for International Partnerships, Jutta Urpilainen. It included 60 members and 10 observers, representing European companies and business associations.
The Warsaw-based company, managed by Urszula Sankowska and Piotr Wygocki, applied and was selected, primarily due to its expertise in the field of AI.
“We are proud that we will be able to share our knowledge and support the European Commission in implementing the Global Gateway strategy,” shared Wygocki, co-founder and co-CEO of MIM Solutions.
“Our specialisation is AI, which plays a crucial role in democratising access to highly specialised services worldwide.”
Sankowska, co-CEO of MIM Solutions, said: “Our company implements medical solutions based on AI in global markets. Therefore, we have a good understanding of the needs of our partners outside the EU and the necessity to collaborate with them.
“This is an opportunity for us to support the global healthcare initiatives of the Commission and address challenging issues such as infertility treatment.”
The advisory group will play a key role during the Global Gateway Forum, which will take place in Brussels under the leadership of Ursula von der Leyen on October 25-26.
Ursula von der Leyen, president of the European Commission said: “Global Gateway is the EU’s contribution to narrowing the global investment gap worldwide. It offers sustainable investments in the prosperity and security of our partners as well as for Europe.
“To further scale up the Global Gateway flagship projects, we need both public and private resources.
“The Global Gateway business advisory group will help us to work closer together and deliver faster on the green and digital transitions, boosting the economy of our partners and the EU.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment